CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 189 enrolled
Drug / intervention
pazopanib (GW786034) 400 mg +3 moredrug
Likely dose
pazopanib (GW786034) 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00347919
NCT00347919Phase 2Completed
CompareCT.gov

A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination With Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects With Advanced or Metastatic Breast Cancer With ErbB2 Fluorescence In Situ Hybridization (FISH) Positive Tumors

GlaxoSmithKline·interventional·Posted Jul 4, 2006·Updated Feb 25, 2016

In Brief

A Phase 2 clinical trial evaluating pazopanib (GW786034) 400 mg, lapatinib (GW572016) 1500 mg, and 2 other interventions for Neoplasms, Breast. Completed, enrolled 189 participants across 84 sites in 16 countries.

Detailed Summary

This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with locally advanced or metastatic breast cancer whose tumors overexpress the ErbB2 protein.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms, Breast
CountriesCanada, France, Hungary, India, Israel, Malaysia, Mexico, Pakistan, Peru, Poland, Russia, Singapore, South Korea, Thailand, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 4, 2006
Enrollment StartJul 1, 2006
Primary CompletionAug 1, 2008
Study CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 20.0 years ago

Interventions

pazopanib (GW786034) 400 mgdrug

400 mg administered orally once daily

lapatinib (GW572016) 1500 mgdrug

1500 mg administered orally once daily.

lapatinib (GW572016) 1000 mgdrug

1000 mg administered orally once daily

pazopanib (GW786034) 800 mgdrug

800 mg administered orally once daily